PAGE 1 OF 3 PAGES
Amendment No. 49

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

1.	Licen Liberty Hospital Nuclear Medicine Depart	Septemb	In accordance with letter dated September 27, 2019.		4. Expiration Date: April 30, 2021		
Nuclear Medicine Department  2. 2525 Glenn W. Hendren Dr. Liberty, MO 64069			3. Licens	3. License number: 24-16178-01 is amended in its entirety to read as follows:		5. Docket No.: 030-10532 Reference No.:	
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical form	8.	Maximum amount that licens may possess at any one time under this license		Authorized use
A.	Any byproduct material permitted by 10 CFR 35.100	Α.	Any S	Α.	As Needed	Α.	Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B.	Any byproduct material permitted by 10 CFR 35.200	B.	Any	<b>B</b> .	As Needed	В.	Any imaging and localization study permitted by 10 CFR 35.200.
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any	C.	1 curie total	C.	For any use permitted by 10 CFR 35.300.
D.	Palladium-103 permitted by 10 CFR 35.400	D.	Sealed Sources (Theragenics Corporation, Model TheraSeed 200)	D.	1 curie total	D.	Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E.	Uranium- depleted in Uranium-235	E.	Metal	E.	12 kilograms per source and 48 kilograms total	E.	Shielding in ADAC Laboratories MCD-AC attenuation correction system.

NRC FORM 374A	U.S. NUCLEAR REGULAT	PAGE 2 OF 3 PAGES	
MATERIALS LICENSE	License Number 24-16178-01	Docket or Reference Number 030-10532	
SUPPLEMENTARY SHEET	Amendment No. 49		

## CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at:
  - A. 2525 Glenn W. Hendren Dr., Liberty, Missouri, 64068
  - B. 2521 Glenn W. Hendren Dr., Liberty, Missouri, 64068
- 11. The Radiation Safety Officer (RSO) for this license is Joseph Caresio, M.D.
- 12. Licensed material shall only be used by, or under the supervision of:

Authorized User(M.D. D.O. etc.) Material and Use

- A. Individuals permitted to work as either authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Osertivi.D.,D.O.,etc.)	Waterial and OSE
Joseph Caresio, M.D.	10 CFR 35.100,10 CFR 35.200
Scott C. Cozad, M.D.	10 CFR 35.400
Daniel H. Dunker, M.D.	10 CFR 35.100,10 CFR 35.200
Michael P. Green, D.O.	10 CFR 35.100,10 CFR 35.200
John I. Halloran, <b>M</b> .D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Andrew Harmon, <b>M</b> .D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Christine Keesling, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Robert A. MacNaughton, II, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Randall C. Newth, M.D.	10 CFR 35.100,10 CFR 35.200
Robert C. Newth, M.D.	10 CFR 35.100,10 CFR 35.200,10 CFR 35.300
Amy K. Patel, M.D.	10 CFR 35.100,10 CFR 35.200

NRC FORM 374A	U.S. NUCLEAR REGULAT	PAGE 3 OF 3 PAGES	
MATERIALS LICENSE	License Number 24-16178-01	Docket or Reference Number 030-10532	
SUPPLEMENTARY SHEET	Amendment No. 49		
			,
Authorized User(M.D.,D.O.,etc.)	Material and Use		

John Brian Pope, M.D.

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide

I-131)

Timothy G. Raveill, M.D.

10 CFR 35.100,10 CFR 35.200

Dwarakraj Soundarraj, M.D.

10 CFR 35.200

- 13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated September 21, 2010 (ML102780663)
  - B. Facsimile dated March 16, 2011 (ML110750577)
  - C. Facsimile dated March 17, 2011 (ML110760650)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: <u>DEC **26** 2019</u>

Sara A. Forster

Region 3